Dr Kami Maddocks shares highlights from ASH 2025, including how the phase 3 EPCORE FL‑1 trial, adding a bispecific antibody to R2 in second‑line or later follicular lymphoma, showed significantly ...
John Mascarenhas, MD, comments on advances in myelofibrosis therapy highlighted at SOHO 2025, including results from key trials exploring combination approaches in JAK inhibitor-naive patients. The ...
First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is underway, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback